Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aptamer Group Plc ( (GB:APTA) ) just unveiled an announcement.
Aptamer Group has raised £4.275m through a placing and subscription of new shares at 0.6p each, receiving strong backing from existing and new investors and participation from its directors. The fundraising is complemented by a separate retail offer of up to £0.5m for existing shareholders, also at 0.6p per share, which the company may increase subject to demand.
The capital injection, on top of a previously reported £1.5m cash balance and a funding runway to Q2 2027, is intended primarily to drive growth rather than shore up the balance sheet. Management expects the new funds to extend the cash runway to 2028, support a pathway toward EBITDA breakeven, and accelerate development of its AI model for RNA-binding proteins and transcription factors as well as in‑vivo data generation for its targeted radiopharmaceutical programme.
The placing shares are split between firm and conditional tranches, with initial admission of the firm placing shares to trading on AIM expected on 31 March 2026 and the remaining placing, subscription and any retail offer shares subject to shareholder approval at a general meeting in April. Investors in the placing and subscription will also receive one warrant for every three shares subscribed, exercisable at a 50% premium to the issue price over two years, offering additional upside exposure if Aptamer’s growth strategy delivers.
The most recent analyst rating on (GB:APTA) stock is a Sell with a £0.62 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Spark’s Take on APTA Stock
According to Spark, TipRanks’ AI Analyst, APTA is a Underperform.
The score is primarily held down by very weak financial performance (sharp revenue collapse, continued losses, and negative cash flows). Technical indicators also remain bearish with the stock below major moving averages and negative MACD; oversold momentum readings provide only limited support. Valuation is constrained by a negative P/E and no dividend data.
To see Spark’s full report on APTA stock, click here.
More about Aptamer Group Plc
Aptamer Group is a UK-based developer of next-generation synthetic binders for the life sciences industry, producing Optimer binders that mimic antibodies by targeting specific molecules in medicine, diagnostics and research. Operating a fee-for-service model in the antibody-alternatives market and partnering with major pharmaceutical companies, it also builds Optimer assets aimed at generating future licensing revenue.
Founded in 2008 and headquartered in York, the company listed on London’s AIM market in 2021, positioning itself within the fast-growing market for high-stability, lower-cost alternatives to traditional antibodies.
Average Trading Volume: 4,829,999
Technical Sentiment Signal: Sell
Current Market Cap: £16.86M
Find detailed analytics on APTA stock on TipRanks’ Stock Analysis page.